Proton therapy and src family kinase inhibitor combined treatments on U87 human glioblastoma multiforme cell line

Autor: Francesco P Cammarata 1, 2, Filippo Torrisi 2, 3, Giusi I Forte 1, Luigi Minafra 1, Valentina Bravatà 1, Pietro Pisciotta 2, 4, Gaetano Savoca 1, Marco Calvaruso 1, Giada Petringa 2, Giuseppe AP Cirrone 2, Anna L Fallacara 5, 6, Laura Maccari 5, Maurizio Botta 5, Silvia Schenone 7, Rosalba Parenti 3, Giacomo Cuttone 2, Giorgio Russo 1

Publikováno v: International Journal of Molecular Sciences
Volume 20
Issue 19
International Journal of Molecular Sciences, Vol 20, Iss 19, p 4745 (2019)
International journal of molecular sciences (Online) 20 (2019): 4745. doi:10.3390/ijms20194745
info:cnr-pdr/source/autori:Francesco P Cammarata 1,2*, Filippo Torrisi 2,3, Giusi I Forte 1,2, Luigi Minafra 1,2, Valentina Bravatà 1,2, Pietro Pisciotta 2,4, Gaetano Savoca 1, Marco Calvaruso 1,2, Giada Petringa 2,3, Giuseppe AP Cirrone 2, Anna L Fallacara 5,6, Laura Maccari 5, Maurizio Botta 5,6, Silvia Schenone 7, Rosalba Parenti 3, Giacomo Cuttone 2 and Giorgio Russo 1,2/titolo:Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line./doi:10.3390%2Fijms20194745/rivista:International journal of molecular sciences (Online)/anno:2019/pagina_da:4745/pagina_a:/intervallo_pagine:4745/volume:20

Glioblastoma Multiforme (GBM) is the most common of malignant gliomas in adults with an exiguous life expectancy. Standard treatments are not curative and the resistance to both chemotherapy and conventional radiotherapy (RT) plans is the main cause

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::566a37fe18d8f0e58ace3bad736c6770
http://hdl.handle.net/11567/983533